Compare
AbbVie vs Vir Biotechnology (ABBV vs VIR)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Vir Biotechnology (VIR) +126.1%; so far this year the figures are +27.5% and +102.5%.
AbbVie is the larger company by market value, about 246.4 times the size of Vir Biotechnology.
Revenue grew +10.7% at ABBV and +1696.0% at VIR over the last year.
ABBV yields 2.38%. VIR pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | VIR | |
|---|---|---|
| Price | $291.31 | $12.21 |
| 1-day | +1.07% | +10.80% |
| YTD | +27.49% | +102.49% |
| 1 year | +34.39% | +126.11% |
| 3 years | +104.47% | +56.74% |
| Market cap | $514.9B | $2.1B |
| P/E | 50.1 | — |
| P/S | 7.80 | 6.91 |
| P/B | — | 2.33 |
| Revenue growth | +10.70% | +1696.00% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | 22.6 |
| Net margin % | 15.7 | -61.0 |
| ROE % | — | -20.6 |
| Debt / equity | — | 0.00 |
| FCF yield % | 3.7 | -6.8 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 1.74 |
| RSI (14) | 59.7 | 59.9 |
| Technical rating |